Amgen acquires Teneobio for US$2.5 billion to consolidate its leading position in new antibody drugs

Robert Galbraith—Reuters

News summary

Amgen will pay an upfront payment of US$900 million to acquire Teneobio, a biotechnology company with technology for the discovery and development of antibody drugs

 

On July 27th, Amgen and Teneobio announced an agreement under which Amgen agreed to acquire Teneobio

It is understood that Amgen already has antibody platform technology, the platform has developed drugs approved by the FDA , as well as more therapeutic candidates that are still under development

medcitynews

Amgen's antibody technology BiTE (abbreviation for bispecific T cell adaptor) produces a drug composed of two antibodies, one binding to the antigen on the tumor and the other binding to CD3 (a protein on T cells)

Teneobio’s new T cell engager platform expands Amgen’s current leadership position in bispecific T cell engagers by providing a differentiated but complementary approach to Amgen’s current BiTE platform

"Teneobio's antibody platform complements our existing capabilities and may provide us with more diverse building blocks that can be developed into new multispecific therapies," said David Reese, Executive Vice President of Amgen Research and Development, in a preparation The good statement said.

Teneobio's product pipeline includes bispecific and multispecific antibody drugs, some of which are being developed in cooperation with other companies

On June 24 this year, AbbVie reached an agreement to acquire the subsidiary TeneoOne and its Phase 2 treatment candidates

The results of the interim analysis of the first phase of TNB-383B clinical trial were outstanding, which made AbbVie decide to acquire TeneoOne

Multiple myeloma is considered to be the second most common blood cancer, second only to acute lymphatic leukemia

The acquisition will also add TNB-585 to Amgen’s R&D pipeline, a bispecific T cell adapter for the treatment of metastatic castration-resistant prostate cancer (mCRPC), currently in phase 1 clinical trials; and Several pre-clinical oncology pipeline assets with the potential for recent new drug clinical trials (IND) declarations

David M.

"The Teneobio team is very pleased to join forces with Amgen, a pioneer in biotherapeutics.

 

Robert Galbraith—Reuters

Robert Galbraith—Reuters

News summary

News summary News summary

Amgen will pay an upfront payment of US$900 million to acquire Teneobio, a biotechnology company with technology for the discovery and development of antibody drugs

Amgen will pay an upfront payment of US$900 million to acquire Teneobio, a biotechnology company with technology for the discovery and development of antibody drugs

On July 27th, Amgen and Teneobio announced an agreement under which Amgen agreed to acquire Teneobio

Amgen will acquire all issued shares of Teneobio at the close of the market with an upfront payment of US$900 million, as well as future milestone payments to Teneobio equity holders that may be as high as US$1.
6 billion
.
Amgen will acquire all issued shares of Teneobio at the close of the market with an upfront payment of US$900 million, as well as future milestone payments to Teneobio equity holders that may be as high as US$1.
6 billion
.

It is understood that Amgen already has antibody platform technology, the platform has developed drugs approved by the FDA , as well as more therapeutic candidates that are still under development
.
But at Teneobio, Amgen saw an attractive antibody drug discovery and development alternative technology
.
According to Amgen, Teneobio's capabilities will help it develop new molecules with the potential to treat multiple diseases
.
The acquisition includes Teneobio’s proprietary bispecific and multispecific antibody technology, which will significantly accelerate the speed and efficiency of the discovery and development of new molecules, which may be used to treat Amgen.
Various important diseases in the core treatment area
.
These platforms complement Amgen’s existing antibody capabilities by adding a heavy-chain antibody platform that allows for streamlined, sequence-based discovery methods for target binders
.

FDA

medcitynews

Amgen's antibody technology BiTE (abbreviation for bispecific T cell adaptor) produces a drug composed of two antibodies, one binding to the antigen on the tumor and the other binding to CD3 (a protein on T cells)
.
Teneobio has also developed a bispecific T cell adaptor, and Amgen says this technology will complement BiTE
.
But Teneobio has an additional technology, TeneoSeek, for the development of multispecific antibodies, which the company calls "UniAbs"
.
The biotechnology company said that TeneoSeek can quickly identify a large number of unique binding molecules for specific therapeutic targets
.
According to Teneobio, this technology can produce multi-specific therapeutic proteins that can target multiple targets and go further than currently available antibody drugs
.

Teneobio’s new T cell engager platform expands Amgen’s current leadership position in bispecific T cell engagers by providing a differentiated but complementary approach to Amgen’s current BiTE platform
.

"Teneobio's antibody platform complements our existing capabilities and may provide us with more diverse building blocks that can be developed into new multispecific therapies," said David Reese, Executive Vice President of Amgen Research and Development, in a preparation The good statement said.
"In addition, the availability of Teneobio's CD3 adaptor technology will allow us to expand the ability to generate bispecifics and use our own technology to tailor the T cell junction domain of the molecule to the disease and target
.
"

Teneobio's product pipeline includes bispecific and multispecific antibody drugs, some of which are being developed in cooperation with other companies
.
GlaxoSmithKline (GSK) and Johnson & Johnson subsidiary Janssen are Teneobio's partners to develop multispecific antibodies against cancer
.
Through a subsidiary called TeneoOne, Teneobio has also formed an alliance with AbbVie to focus on the development of the bispecific antibody TNB-383B against multiple myeloma
.

On June 24 this year, AbbVie reached an agreement to acquire the subsidiary TeneoOne and its Phase 2 treatment candidates
.
According to the agreement, TeneoOne can obtain an advance payment of US$90 million and is responsible for the phase I clinical study of TNB-383B
.
And AbbVie can acquire TeneoOne's exclusive selection of Quanhe and lead the follow-up development and promotion of TNB-383B rights
.
TNB-383B is a fully human BCMA/CD3 double antibody that uses KIH technology to pair fixed light chain (FLC) and heavy chain (HCO).
FLC can weakly activate CD3, and HCO has two high-affinity anti-BCMA groups.
Regiment
.
TNB-383B also has a silent human IgG4 Fc segment, which can limit non-specific activation and has a longer half-life
.

The results of the interim analysis of the first phase of TNB-383B clinical trial were outstanding, which made AbbVie decide to acquire TeneoOne
.
This clinical trial mainly evaluates the safety, clinical pharmacology and clinical activity of patients with relapsed/refractory multiple myeloma (n=24) who have previously received at least 3 lines of treatment after receiving TNB-383B
.
The results showed that in the dose-escalation group, the objective response rate (ORR) of TNB-383B was 79% when the dose was ≥ 40 mg, the very good partial response rate (VGPR) was 63%, and the complete response rate (CR) was 29%.

.
When the median tracking time was 6.
1 months, the median duration of response (DOR) had not yet been reached
.

Multiple myeloma is considered to be the second most common blood cancer, second only to acute lymphatic leukemia
.
There are approximately 160,000 newly diagnosed cases worldwide each year, accounting for more than 10% of all blood cancers
.
The global drug market for this disease in 2020 is 8.
3 billion U.
S.
dollars and is expected to reach 17.
5 billion U.
S.
dollars by 2027, with a compound annual growth rate of approximately 11.
2%
.

The acquisition will also add TNB-585 to Amgen’s R&D pipeline, a bispecific T cell adapter for the treatment of metastatic castration-resistant prostate cancer (mCRPC), currently in phase 1 clinical trials; and Several pre-clinical oncology pipeline assets with the potential for recent new drug clinical trials (IND) declarations
.
TNB-585 is a supplement to Amgen's existing prostate cancer product portfolio, including acapatamab (formerly known as AMG 160) and AMG 509 in phase 1 clinical trials
.

David M.
Reese, MD, Executive Vice President of Amgen R&D, said: "The acquisition of Teneobio will strengthen our ability to develop innovative drugs for patients with severe diseases and bring potential'best-in-class' products to the market, especially for us.

Multispecific and bispecific drugs for a wide range of disease targets in the core therapeutic field.
Teneobio's antibody platform complements our existing capabilities and may provide us with a more diverse set of new multispecific therapies that can be developed Drug building block
.
In addition, Teneobio’s CD3 binder technology will broaden our ability to generate bispecific antibodies.
Through our own technology, we can customize the T cell binding domain of molecules according to diseases and targets
.
"

In addition, Teneobio's CD3 binder technology will broaden our ability to generate bispecific antibodies.
Through our own technology, we can customize the T cell binding domain of molecules according to diseases and targets
.
" In addition, Teneobio's CD3 binder technology will broaden our ability to generate bispecific antibodies.
Through our own technology, we can customize the T cell binding domain of molecules according to diseases and targets
.
"

"The Teneobio team is very pleased to join forces with Amgen, a pioneer in biotherapeutics.
Amgen's R&D resources and extensive clinical experience in immuno- oncology are very suitable for the application and advancement of Teneobio's differentiated technology and multispecific antibodies," Teneobio Chief Executive Officer Officer Dr.
Roland Buelow said, “In the past 5 years, Teneobio has developed leading expertise in effectively designing differentiated multispecific and bispecific therapies for many indications, compared with the first generation of T cell adaptors.
, Has potentially better safety, efficacy and pharmacokinetic characteristics
.
In short, we are working together to quickly discover, develop and provide new and meaningful disease-modifying multispecific antibodies to patients in need
.
"

Immunization " In the past 5 years, Teneobio has developed leading expertise in effectively designing differentiated multispecific and bispecific therapies for many indications, which is potentially better than the first generation of T cell adaptors.
The safety, efficacy and pharmacokinetic characteristics of the drug
.
In short, we are working together to quickly discover, develop and provide new and meaningful disease-modifying multispecific antibodies to patients in need
.
" "In the past 5 years , Teneobio has developed leading expertise in effectively designing differentiated multi-specific and bi-specific therapies for many indications.
Compared with the first generation of T cell adapters, Teneobio has potentially better safety, effectiveness and Pharmacokinetic characteristics
.
In short, we are working together to quickly discover, develop and provide new and meaningful disease-modifying multispecific antibodies to patients in need
.
"

 

Reference materials:

Reference materials: 1.
  https://medcitynews.
com/2021/07/amgen-adds-antibody-assets-and-rd-tech-with-900m-teneobio-acquisition/?rf=1 1.
  https://medcitynews .
com/2021/07/amgen-adds-antibody-assets-and-rd-tech-with-900m-teneobio-acquisition/?rf=1 2.
Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments.
Retrieved 2021-07-28, from https:// contingent-milestone-payments-301342565.
html https:// -milestone-payments-301342565.
html3.
AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myelom

in this message